FINWIRES · TerminalLIVE
FINWIRES

KRX:326030

8 stories mentioning KRX:326030Updated 7d ago

Every FINWIRES story that references KRX:326030, newest first.

What's the latest news on KRX:326030?

Asia

South Korean Shares Decline Over 3% on Tech Losses, Rising Oil Prices Amid Middle East Tensions

South Korean shares fell more than 3% on Monday as investors sold technology heavyweights amid ongoing geopolitical uncertainty in the Middle East and increasing oil prices.Global and U.S. oil prices extended gains early Monday after attacks on Saudi oil infrastructure and further targeting of commercial vessels in the Strait of Hormuz. Brent crude rose nearly 3% to above $107 a barrel, while West Texas Intermediate crude gained about 3% to approach $103 a barrel.The Korea Composite Stock Price Index, or Kospi, decreased by 225.54 points, or about 3.3%, to close at 6,684.37. The Kosdaq also fell by 13.85 points, or 1.7%, to close at 806.79.In economic news, South Korea's first investment project in the U.S. under the bilateral tariff agreement signed in 2025 is expected to close soon, pending further negotiations, Yonhap News reported Sunday, citing Industry Minister Kim Jung-kwan.South Korea aims to finalize and potentially announce the agreement later this week. The investment project is part of the country's $350 billion investment commitment made in exchange for lowering U.S. reciprocal tariffs to 15% from 25%. Potential destinations comprise a large gas-fired power plant in Texas and a nuclear power project.In corporate news, SK Biopharmaceuticals (KRX:326030) secured a 71.6 billion won pharmaceutical supply agreement for its anti-seizure medication Cenobamate with its US unit SK Life Science, according to a Monday filing with the Korea Exchange.The product is marketed in the US as XCOPRI. Cenobamate is a drug for treating epilepsy.Shares of the company fell nearly 1% at market close.In other news, Samsung Heavy Industries (KRX:010140) secured a 1.408 trillion won contract to build four LNG carriers for an undisclosed Oceania-based client, according to a Monday filing with the Korean Exchange.The contract is expected to be fulfilled by Sept. 28, 2029.Shares of Samsung Heavy Industries added over 3% at market close.

^KOSDAQKOSPIKRX:010140KRX:326030
Asia

SK Biopharmaceuticals Wins KRW71.6 Billion Pharmaceutical Supply Agreement for Epilepsy Drug

SK Biopharmaceuticals (KRX:326030) secured a 71.6 billion won pharmaceutical supply agreement for its anti-seizure medication Cenobamate with its US unit SK Life Science, according to a Monday filing with the Korea Exchange.The product is marketed in the US as XCOPRI. Cenobamate is a drug for treating epilepsy.

KRX:326030
Asia

SK Biopharmaceuticals Signs Deal to In-License Investigational Epilepsy Drug from Biohaven

SK Biopharmaceuticals (KRX:326030) said it has signed a deal to in-license the investigational epilepsy drug opakalim from Biohaven, using its commercial infrastructure to launch and sell its second innovative medicine directly in the U.S. market, according to a Wednesday release.The South Korean drugmaker said it will launch the selective Kv7 potassium channel activator as early as 2029, subject to regulatory conditions, to become the only drug development company to directly market multiple innovative medicines globally.The deal includes $400 million in cash upfront and up to $395 million in development and regulatory milestone payments, and it will also pay tiered royalties to Biohaven on U.S. net sales of opakalim.

KRX:326030
Asia

SK Biopharmaceuticals Signs KRW99 Billion Cenobamate Supply Deal

SK Biopharmaceuticals (KRX:326030) signed a pharmaceutical supply contract worth 99.4 billion won with its US subsidiary, SK Life Science, according to a Tuesday filing with the Korean Exchange.The contract is to supply its epilepsy treatment cenobamate, which is sold in the US market under the brand name, XCOPRI.

KRX:326030
Asia

SK Biopharmaceuticals' Attributable Net Income Surges 158% in Q2; Shares Rise 5%

SK Biopharmaceuticals (KRX:326030) posted a 158% year-over-year jump in net income attributable to owners of the parent to 85.1 billion won from 32.9 billion won for the second quarter.Sales rose 40% to 247.4 billion won from 176.3 billion won for the three months ended June 30.Shares of the pharmaceutical company rose 5% in recent trade.

KRX:326030
Asia

Insilico Medicine, SK Biopharmaceuticals Strike $2.5 Billion AI Drug Discovery Pact

Insilico Medicine (HKG:3696) and SK Biopharmaceuticals (KRX:326030) have signed a drug discovery collaboration deal focused on neuroimmune disorders of the central nervous system, with a total potential value exceeding $2.5 billion, according to a Monday Hong Kong bourse filing.Under the agreement, Insilico will use its artificial intelligence-powered Pharma.AI platform and drug discovery capabilities to identify and optimize drug candidates. Whereas, SK Biopharmaceuticals will lead late-stage development and commercialization, the filing said.Insilico is eligible to receive up to $18 million in upfront and near-term milestone payments. The total potential value of the deal exceeds $2.5 billion, including development, regulatory, and commercial milestones, as well as single-digit royalties on future product sales.The collaboration focuses on neuroimmune diseases and expands Insilico's use of AI-driven drug discovery technologies in central nervous system disorders.

HKG:3696KRX:326030
Asia

South Korean Shares End at Fresh Highs on US-Iran Peace Hopes; SK Biopharma Rises

South Korean stocks closed at a fresh high on Thursday as investor sentiment was buoyed by optimism regarding a potential US-Iran peace agreement.The Korea Composite Stock Price Index or Kospi increased by 105.49 points, or 1.4%, to end at 7,490.05. The Kosdaq slipped 0.9% to close at 1,199.18.The key index was lifted by gains in market heavyweights Samsung Electronics (KRX:005930) and SK Hynix (KRX:000660), which rose more than 2% and 3%, respectively.In economic news, South Korea's foreign reserves grew to $427.9 billion in April from $423.7 billion as of March-end, data from the Bank of Korea showed.In corporate news, SK Biopharmaceuticals (KRX:326030) finished 1% higher after posting a first-quarter attributable income of 105.2 billion won, up 351% from 23.3 billion won a year earlier.

^KOSDAQKOSPIKRX:000660KRX:005930KRX:326030
Asia

SK Biopharmaceuticals' Net Income Jumps 351% in Q1

SK Biopharmaceuticals (KRX:326030) posted first-quarter net income attributable to shareholders of 105.2 billion won, up 351% from 23.3 billion won a year earlier, according to a Thursday filing with the Korea Exchange.The South Korean biopharmaceutical firm's sales rose 58% year over year to 227.9 billion won from 144.4 billion won.Shares of SK Biopharmaceuticals rose more than 2% in recent trade.

KRX:326030

Track with the FINWIRES app suite